Tilray | TRLY - Assets


Tilray reported $2.1B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acasti Pharma USD 50.07M 18.42M Jun/2026
Akebia Therapeutics USD 342.13M 7.53M Sep/2026
Alaunos Therapeutics USD 1.52M 367K Jun/2026
Aurora Cannabis CAD 620.88M 19.79M Jun/2026
Avita Medical AUD 47.78M 8.62M Jun/2026
Canopy Growth CAD 1.1B 14.81M Jun/2026
Cronos Group USD 1.2B 18.15M Sep/2026
Dianthus Therapeutics USD 1.28B 62.98M Sep/2026
Divis Laboratories Ltd INR 219.64B 19.31B Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
IQVIA Holdings USD 30.47B 593M Sep/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Moderna USD 13.47B 2.51B Sep/2026
Organigram Holdings CAD 820.26M 298.95M Jun/2026
Organon & Co USD 13.4B 223M Sep/2026
Revvity USD 11.49B 555.49M Sep/2026
Tectonic Therapeutic USD 237.03M 9.54M Jun/2026
Tilray USD 2.1B 15.95M Sep/2025
Viatris USD 34.68B 362M Sep/2026
Xeris Pharmaceuticals USD 423.22M 11.31M Sep/2026
Zealand Pharma A/S 15.3B 647.8M Mar/2026